Costs associated with adverse events from remission induction for children with Acute Lymphoblastic Leukemia (ALL)

• Main Authors: Eréndira Mejía-Aranguré (Author), Alfonso Reyes-López (Author), Luis Enrique Juárez-Villegas (Author), Yosef Olaf Hernández-Olivares (Author), Alberto Daniel Saucedo-Campos (Author), Gabriela Hernández-Pliego (Author), Silvia Martínez-Valverde (Author), Leticia A. Barajas-Nava (Author), Juan Garduño-Espinosa (Author)
• Format: Book
• Published: BMC, 2022-12-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Abstract Background ALL is the most frequent hematological tumor in children, so during remission induction chemotherapy protocol (RICP) adverse events (AEs) may appear. The public program in Mexico in charge of financial support to oncologic children without social security delivered a fix amount f...